Pharmacogenetics as Alien science:: Alzheimer's disease, core sets and expectations

Social Studies of Science

Volumn 36, Issue 5, 2006, Pages 723-752

  Hedgecoe, Adam ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

APOE; Core set; Expectations; Genomics; Pharmacogenetics; Policy makers

Indexed keywords

EID: 33748436043     PISSN: 03063127     EISSN: 14603659     Source Type: Journal    
DOI: 10.1177/0306312706059746     Document Type: Article

References (125)

1. Abraham, John (1995) Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation (London: UCL/St Martins Press).
2. Akhtar, Saghir (2002) ' Pharmacogenomics: Are Pharmacists Ready for Genotyped Prescribing? ', Pharmaceutical Journal 268 (2 March). 296 - 299.
3. Almkvist, O., V. Jelic, K. Amberla, E. Hellstrom-Lindhal, L. Meuling & A. Nordberg (2001) ' Responder Characteristics to a Single Oral Dose of Cholinesterase Inhibitor: A Double-Blind Placebo-Controlled Study with Tacrine in Alzheimer Patients ', Dementia and Geriatric Cognitive Disorders 12 (1). 22 - 32.
4. Á lvarez, X.A., R. Mouzo, V. Pichel, P. Perez, M. Laredo, L. Fernandez-Novoa, et al. (1999) ' Double-Blind Placebo-Controlled Study with Citicoline in APOE Genotyped Alzheimer's Disease Patients: Effects on Cognitive Performance, Brain Bioelectrical Activity and Cerebral Perfusion ', Methods and Findings in Experimental and Clinical Pharmacology 21 (9). 633 - 644.
5. American Geriatric Society Ethics Committee (2001) ' Genetic Testing for Late-Onset Alzheimer's Disease ', Journal of the American Geriatric Society 49: 225 - 226.
6. Anderson, Wayne, Craig Fitzgerald & Penelope Manasco (1999) ' Current and Future Applications of Pharmacogenomics ', New Horizons: Science and Practice of Acute Medicine 7 (2) (April). 262 - 269.
7. Arksey, H. (1994) ' Expert and Lay Participation in the Construction of Medical Knowledge ', Sociology of Health and Illness 16 (4). 448 - 468.
8. Arledge, Teresa, Andrew Freeman, Julian Arbuckle, Michael Mosteller & Penelope Manasco (2000) ' Applications of Pharmacogenetics to Drug Development: The Glaxo Wellcome Experience ', Drug Metabolism Reviews 32 (3/4). 387 - 394.
9. Babić, Tomislav, Darija Mahović Lakui ć, Jadranka Serti ć, Mladen Petrovećki & Ana Stavlejenić-Rukavina (2004) ' ApoE Genotyping and Response to Galanthamine in Alzheimer's Disease-A Real Life Retrospective Study ', Collegium Anthropologicum 28 (1). 199 - 204.
10. Bailey, David, Alexander Bondar & L. Mike Furness (1998) ' Pharmacogenomics-It's not just Pharmacogenetics ', Current Opinion in Biotechnology 9: 595 - 601.
11. Barton, Gary (2000) Genetic Services in the NHS: An Institute of Healthcare Management Discussion Paper (London: The Stationery Office).
12. Bogdanovic, Sreten & Beata Langlands (1999) Pharmacogenomics Players (London: Financial Times).
13. Borroni, Barbara, Francesca Colciaghi, Lucia Pastorino, Silvana Archetti, Paola Corsini, F. Cattabeni et al. (2002) ' ApoE Genotype Influences the Biological Effect of Donepezil on APP Metabolism in Alzheimer Disease: Evidence from a Peripheral Model ', European Neuropsychopharmacology 12: 195 - 200.
14. Bracco, Laurent (2002) ' Pharmacogenomics and Personalised Medicine ', Pharmacogenomics 3 (2). 166 - 171.
15. Brill-Edwards, Michelle (1999) ' Canada's Health Protection Branch: Whose Health, What Protection? ', in M.L. Barer, K.M. McGrail, K. Cardiff, L. Wood & C.J. Green (eds), Tales from the Other Drug Wars. Papers from the 12th Annual Health Policy Conference, Vancouver, BC (26 November). University of British Columbia, Centre for Health Services and Policy Research. < www.chspr.ubc.ca/misc/drugwars2.pdf >.
16. Brown, Nik (2003) ' Hope against Hype-Accountability in Biopasts, Presents and Futures ', Science Studies 2: 3 - 21.
17. Brown, Nik & Mike Michael (2003) ' A Sociology of Expectations: Retrospecting Prospects and Prospecting Retrospects ', Technology Analysis and Strategic Management 15 (1). 3 - 18.
18. Brown, Nik, Brian Rappert & Andrew Webster (eds) (2000) Contested Futures: A Sociology of Prospective Science and Technology (Aldershot, Hants.: Ashgate).
19. Bullock, Roger (2002) ' New Drugs for Alzheimer's Disease and Other Dementias ', British Journal of Psychiatry 180: 135 - 139.
20. Cacabelos, Ramón (2002) ' Pharmacogenomics for the Treatment of Dementia ', Annals of Medicine 34: 357 - 379.
21. Cacabelos, Ramón, Antón Alvarez, Valter Lombardi, Lucía Fernandez-Novoa, Lola Corzo, Paula Perez et al. (2000) ' Pharmacological Treatment of Alzheimer's Disease: From Psychotropic Drugs and Cholinesterase Inhibitors to Pharmacogenomics ', Drugs of Today 36 (7). 415 - 499.
22. Chamberlain, John & Pieter Joubert (2001) ' Opportunities and Strategies for Introducing Pharmacogenetics into Early Drug Development ', Drug Discovery Today 6 (11) (June). 569 - 574.
23. Collins, H.M. (1985) Changing Order: Replication and Induction in Scientific Practice (London: Sage Publications).
24. Collins, H.M. (1996) ' Expertise: Between the Scylla of Certainty and the New Age Charybdis ', Accountability in Research 5: 127 - 135.
25. Collins, H.M. (1999) ' Tantalus and the Aliens: Publications, Audiences and the Search for Gravitational Waves ', Social Studies of Science 29 (2). 163 - 197.
26. Crentsil, Victor (2004) ' The Pharmacogenomics of Alzheimer's Disease ', Ageing Research Reviews 3: 153 - 169.
27. Cummings, Jeffrey (2003) ' Use of Cholinesterase Inhibitors in Clinical Practice ', American Journal of Geriatric Psychiatry 11 (2). 131 - 145.
28. Davis, Peter (ed.) (1996) Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs (Oxford: Oxford University Press).
29. Economist (1997) ' Drug Companies' Target Practice ', Economist (6 December). 94 - 95.
30. Edmond, Gary (2001) ' The Law-Set: The Legal-Scientific Production of Medical Propriety ', Science, Technology, & Human Values 26 (2). 191 - 226.
31. Emilien, G., M. Ponchon, C. Caldas, O. Isacson & J.M. Maloteaux (2000) ' Impact of Genomics on Drug Discovery and Clinical Medicine ', Quarterly Journal of Medicine 93 (7). 391 - 423.
32. Ensom, Mary, Thomas Chang & Payal Patel (2001) ' Pharmacogenetics: The Therapeutic Drug Monitoring of the Future ', Clinical Pharmacokinetics 40 (11). 783 - 802.
33. Evans, William & Julie Johnson (2001) ' Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response ', Annual Review of Genomics and Human Genetics 2: 9 - 39.
34. Evans, William & Howard McLeod (2003) ' Pharmacogenomics-Drug Disposition, Drug Targets and Side Effects ', New England Journal of Medicine 348 (6). 538 - 549.
35. Evans, William & Mary Relling (1999) ' Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics ', Science 286 (15 October). 487 - 491.
36. Farlow, Martin, Stephen Gracon, Linda Hershey, Karen Lewis, Carl Sadowsky & Jan Dolan-Ureno (1992) ' A Controlled Trial of Tacrine in Alzheimer's Disease ', Journal of the American Medical Association 268 (18). 2523 - 2529.
37. Farlow, Martin, Debomoy Lahiri, Judes Poirier, Jean Davignon & Siu Hui (1996) ' Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy ', Annals of the New York Academy of Science 802: 101 - 110.
38. Farlow, M.R., D.K. Lahiri, J. Poirier, J. Davignon, L. Schneider & S.L. Hui (1998) ' Treatment Outcome of Tacrine Therapy Depends on Apolipoprotein E Genotype and Gender of the Subject with Alzheimer's Disease ', Neurology 50: 669 - 677.
39. Ferentz, Ann (2002) ' Integrating Pharmacogenomics into Drug Development ', Pharmacogenomics 3 (4). 453 - 467.
40. Frisoni, Giovanni (2001) ' Treatment of Alzheimer's Disease with Acetylcholinesterase Inhibitors: Bridging the Gap between Evidence and Practice ', Journal of Neurology 248: 551 - 557.
41. Geels, Frank W. & Wim A. Smit (2000) ' Failed Technology Futures: Pitfalls and Lessons from a Historical Survey ', Futures 32 (9). 867 - 885.
42. GenomeWeb (2001) 'Pharmacogenomics Seen Growing to $6B by 2005, Report Says', < www.genomeweb.com/articles/view.asp?Article = 20017355957 >.
43. Goldsbrough, Peter, Pete Lawyer & Gayatri Sondhi (1999) The Pharmaceutical Industry into its Second Century: from Serendipity to Strategy (Boston, MA: Boston Consulting Group).
44. Hall, Celia (1995) ' Makers Appeal for Alzheimer's Drug Licence ', The Independent (22 March). 4-4.
45. Hedgecoe, Adam (2000) Narratives of Geneticization: Cystic Fibrosis, Diabetes and Schizophrenia. Unpublished PhD Thesis, University of London
46. Hedgecoe, Adam (2003) ' Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics ', Science, Technology, & Human Values 28 (4). 513 - 537.
47. Hedgecoe, Adam (2004) The Politics of Personalised Medicine- Pharmacogenetics in the Clinic. (Cambridge: Cambridge University Press).
48. Hedgecoe, Adam & Paul Martin (2003) ' The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics ', Social Studies of Science 33 (3). 327 - 364.
49. Hunt, Liz (1996) ' Unravelling the Tangles of Dementia ', The Independent on Sunday, Sunday Review (28 April). 42-42.
50. Ingelman-Sundberg, Magnus (2001) ' Pharmacogenetics: An Opportunity for a Safer and More Efficient Pharmacotherapy ', Journal of Internal Medicine 250: 186 - 200.
51. Jazwinska, Elizabeth (2001) ' Exploiting Human Genetic Variation in Drug Discovery and Development ', Drug Discovery Today 6 (4) (February). 198 - 205.
52. Johnson, Julie & William Evans (2002) ' Molecular Diagnostics as a Predictive Tool: Genetics of Drug Efficacy and Toxicity ', Trends in Molecular Medicine 8 (6). 300 - 305.
53. Kleyn, Patrick & Elliot Vesell (1998) ' Genetic Variation as a Guide to Drug Development ', Science 281 (18 September). 1820 - 1821.
54. Knopman, D.S., S.T. DeKosky, J.L. Cummings, H. Chui, J. Corey-Bloom, N. Relkin et al. (2001) ' Practitioner Parameter: Diagnosis of Dementia (An Evidence Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology', Neurology 56: 1143 - 1153.
55. Krall, Wanda, John Sramek & Neal Cutler (1999) ' Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer's Disease ', Annals of Pharmacology 33: 441 - 450.
56. Kuivenhoven, Jan Albert, J. Wouter Jukema, Aeilko Zwinderman, Peter de Knijff, Ruth McPherson, Albert Bruschke et al. (1998) ' The Role of a Common Variant of the CETP Gene in the Progression of Coronary Atherosclerosis ', New England Journal of Medicine 338 (2) (8 January 1998). 86 - 93.
57. Kurth, Janice (2000) ' Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk ', Drug Information Journal 34: 223 - 227.
58. Lahiri, Debomoy, Martin Farlow, Nigel Greig & Kumar Sambamurti (2002) ' Current Drug Targets for Alzheimer's Disease Treatment ', Drug Development Research 56: 267 - 281.
59. Lanctt, Krista, Nathan Hermann & Maysoon LouLou (2003) ' Correlates of Response to Acetylcholinesterase Inhibitor Therapy in Alzheimer's Disease ', Journal of Psychiatry and Neuroscience 28 (1). 13 - 26.
60. Latour, Bruno (1987) Science in Action: How to Follow Scientists and Engineers through Society (Cambridge, MA: Harvard University Press).
61. Lau, Kit Fun & Hakan Sakul (2000) ' Chapter 23: Pharmacogenomics ', in J. Allen (ed.), Annual Reports in Medicinal Chemistry (Elsevier). 261 - 269.
62. Lehman Brothers (2001) The Fruits of Genomics (New York: Lehman Brothers).
63. Liggett, Stephen (2001) ' Pharmacogenetic Applications of the Human Genome Project ', Nature Medicine 7 (3). 281 - 283.
64. Lindpaintner, Klaus (1999) ' Genetics in Drug Discovery and Development: Challenge and Promise of Individualizing Treatment in Common Complex Disease ', British Medical Bulletin 55 (2). 471 - 491.
65. Lindpaintner, Klaus, Elizabeth Foot, Mark Caulfield & Ian Hall (2001) ' Pharmacogenetics: Focus on Pharmacodynamics ', International Journal of Pharmaceutical Medicine 15: 74 - 82.
66. Lucotte, Gérard, Christiane Oddoze & Bernard-François Michel (1995) ' Apolipoprotein E and Response to Tacrine in French Alzheimer's Disease Patients ', Abstract presented at the International Psychogeriatrics Association Conference, Apolipoprotein E et Maladie d'Alzheimer, 29 May, Paris.
67. McLeod, Howard & William Evans (2001) ' Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy ', Annual Review of Pharmacology and Toxicology 41: 101 - 121.
68. MacGowan, Sian, Margaret Scott, M. Agg & Gordon Wilcock (1995) ' Influence of Apolipoprotien E Genotype on Response to Tacrine in Male and Female Patients with Alzheimer's Disease ', Abstract presented at the International Psychogeriatrics Association Conference, Apolipoprotein E et Maladie d'Alzheimer, 29 May, Paris.
69. MacGowan, Sian, Gordon Wilcock & Margaret Scott (1998) ' Effect of Gender and Apolipoprotein E Genotype on Response to Anticholinesterase Therapy in Alzheimer's Disease ', International Journal of Geriatric Psychiatry 13: 625 - 630.
70. MacKenzie, Donald (1990) Inventing Accuracy: A Historical Sociology of Nuclear Missile Guidance (Cambridge, MA: MIT Press).
71. Maimone, Daude, Roberto Dominici & Luigi Grimaldi (2001) ' Pharmacogenomics of Neurodegenerative Diseases ', European Journal of Pharmacology 413: 11 - 29.
72. Maitland, van der Zee, Anke Helese, Anthonius de Boer & Hubertus Leufkens (2000) ' The Interface between Pharmacoepidemiology and Pharmacogenetics ', European Journal of Pharmacology 410: 121 - 130.
73. Mancinelli, Laviero, Maureen Cronin & Wolfgang Sadée (2000) ' Pharmacogenomics: The Promise of Personalized Medicine ', AAPS PharmSci 2 (1) (7 March). Article 4.
74. March, Ruth (2000) ' Pharmacogenomics: The Genomics of Drug Response ', Yeast 17: 16 - 21.
75. Marshall, Andrew (1997) ' Getting the Right Drug into the Right Patient ', Nature Biotechnology 15: 1249 - 1252.
76. Martin, Paul (1999) ' Genes as Drugs: The Social Shaping of Gene Therapy and the Reconstruction of Genetic Disease ', Sociology of Health and Illness 21: 517 - 538.
77. Michael, Mike & Lynda Birke (1994) ' Enrolling the Core Set: The Case of the Animal Experimentation Controversy ', Social Studies of Science 24: 81 - 95.
78. Moyses, Chris (1999) ' Pharmacogenetics, Genomics, Proteomics: The New Frontiers in Drug Development ', International Journal of Pharmaceutical Medicine 13 (4). 197 - 202.
79. Murphy, Michael (2000) ' Pharmacogenomics: A New Paradigm for Drug Development ', Drug Discovery World (Fall). 1 - 7.
80. Myers, Greg (1990) Writing Biology: Texts in the Social Construction of Scientific Knowledge (Madison, WI: University of Wisconsin Press).
81. Myers, Greg (1991) ' Stories and Styles in Two Molecular Biology Review Articles ', in Charles Bazerman & James Paradis (eds). Textual Dynamics of the Professions (Madison, WI & London: University of Wisconsin Press): 45 - 75.
82. Norton, Ronald (2001) ' Clinical Pharmacogenomics: Applications in Pharmaceutical R&D ', Drug Discovery Today 6 (4) (February). 180 - 185.
83. Nuffield Council on Bioethics (2003) Pharmacogenetics: Ethical Issues: Report of Working Party (London: Nuffield Council on Bioethics).
84. Oddoze, Christiane, Bernard-François Michel, Patrice Berthezene, Christine Clavel & Lucotte Gérard (1998) ' Apolipoprotein E Epsilon 4 Allele Predicts a Positive Response to Tacrine in Alzheimer's Disease ', Alzheimer's Report 1 (1). 13 - 16.
85. Oddoze, Christiane, Bernard-François Michel & Gérard Lucotte (2000) ' Apolipoprotein E Epsilon 4 Allele Predicts a Better Response to Donepezil Therapy in Alzheimer's Disease ', Alzheimer's Report 3 (4). 213 - 216.
86. Oestreicher, Paul (2001) ' 4th Annual Pharmacogenomics and Medicine Lecture: 3 April 20001, New Haven, Connecticut ', Pharmacogenomics 2 (3). 291 - 296.
87. Persing, Bradley & Denis Cheek (2000) ' Pharmacogenomics ', Nursing Clinics of North America 35 (4). 975 - 980.
88. Pharma Marketletter (1999) ' SB Licenses Memris to UK Biotech Cerebrus ', Pharma Marketletter ( 1 June ).
89. Phillips, Kathryn, David Veenstra, Eyal Oren, Jane Lee & Wolfgang Sadée (2001) ' Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: a Systematic Review ', Journal of the American Medical Association 286 (18) (14 November). 2270 - 2279.
90. Poirier, Judes (1999a) ' Apolipoprotein E4, Cholinergic Integrity and the Pharmacogenetics of Alzheimer's Disease ', Journal of Psychiatry and Neuroscience 24 (2). 147 - 153.
91. Poirier, Judes (1999b) ' Apolipoprotein E: A Pharmacogenetic Target for the Treatment of Alzheimer's Disease ', Molecular Diagnosis 4 (4). 335 - 341.
92. Poirier, Judes, Marie-Claude Delisle, Isabelle Aubert, Martin Farlow, Debomoy Lahiri, Siu Hui et al. (1995) ' Apolipoprotein E Allele as a Predictor of Cholinergic Deficits and Treatment Outcome in Alzheimer's Disease ', Proceedings of the National Academy of Sciences 92: 12260 - 12264.
93. Regalado, Antonio (1999) ' Inventing the Pharmacogenomics Business ', American Journal of Health-System Pharmacy 56: 40 - 50.
94. Richard, Florence, Nicole Helbecque, Eric Neuman, Davis Guez, Raymond Levy & Philippe Amouyel (1997) ' APOE Genotyping and Response to Drug Treatment in Alzheimer's Disease ', Lancet 349: 539-539.
95. Riekkinen, Paavo, K. Koivisto, K.J. Reinikaianen, T. Hänninen, M. Hallkainen, P. Kilkku et al. (1998) ' Can apo-4 Subtype Predict Response to Selegiline Treatment in Alzheimer's Disease? ', in E. Giacobini, A. Nordberg, J.-P. Michel, B. Winblad & R. Becker (eds). Proceedings of the 5th International Geneva/Springfield Symposium on Advances in Alzheimer's Therapy (Springfield, IL: Southern Illinois University): 91-91.
96. Rigaud, Anne-Sophie, Latchezar Traykov, L. Caputo, M.C. Guelfi, F. Latour, R. Couderc et al. (2000) ' The Apolipoprotein E [.epsilon]4 Allele and the Response to Tacrine Therapy in Alzheimer's Disease ', European Journal of Neurology 7: 255 - 258.
97. Rioux, Patrice (2000) ' Clinical Trials in Pharmacogenetics and Pharmacogenomics: Methods and Applications ', American Journal of Health System Pharmacy 57 (9). 887 - 898.
98. Robertson, John, Baruch Brody, Allen Buchanan, Jeffery Kahn & Elizabeth McPherson (2002) ' Pharmacogenetic Challenges for the Health Care System ', Health Affairs 21 (4). 155 - 167.
99. Roden, Dan & Alfred George (2001) ' The Genetic Basis of Variability in Drug Responses ', Nature Reviews Drug Discovery 1: 37 - 44.
100. Roses, A.D. (2000) ' Pharmacogenetics and the Future Drug Development and Delivery ', Lancet 355 (15 April). 1358 - 1361.
101. Roses, Allen (2002a) ' Genome-Based Pharmacogenetics and the Pharmaceutical Industry ', Nature Reviews Drug Discovery 1: 541 - 549.
102. Roses, Allen (2002b) ' Pharmacogenetics' Place in Modern Medical Science and Practice ', Life Sciences 70: 1471 - 1480.
103. Royal Society (2005) Personalised Medicines: Hopes and Realities (London: Royal Society).
104. Rusnak, J., R. Kisabeth, D. Herbert & D. McNeil (2001) ' Pharmacogenomics: A Clinician's Primer on Emerging Technologies for Improves Patient Care ', Mayo Clinic Proceedings 76: 299 - 309.
105. Sadée, Wolfgang (1999) ' Pharmacogenomics ', British Medical Journal 319: 1286-1286.
106. Saunders, A.M., W.J. Strittmatter, D. Schmechel, P.H.S. Georgehyslop, M.A. Pericak Vance, S.H. Joo et al. (1993) ' Association of Apolipoprotein-E Allelle Epsilon-4 with Late-Onset Familial and Sporadic Alzheimer's Disease ', Neurology 43 (8). 1467 - 1472.
107. Schappert, Keith, Pierre Sevigny & Judes Poirier (2002) ' Apolipoprotein E as a Marker in the Treatment of Alzheimer's Disease ', in Bernard Lerer (ed.), Pharmacogenetics of Psychotropic Drugs (Cambridge: Cambridge University Press). 360 - 371.
108. Schmitz, Gerd, Charalampos Aslanidis & Karl Lackner (2001) ' Pharmacogenomics: Implications for Laboratory Medicine ', Clinica Chimica Acta 308: 43 - 53.
109. Shi, Michael, Michael Bleavins & Felix de la Iglesia (2001) ' Pharmacogenetics Application in Drug Development and Clinical Trials ', Drug Metabolism and Disposition 29 (4) part 2: 591 - 595.
110. Siest, Gérard, Phillippe Bertrand, Bernard Herbeth, Monique Vincent-Viry, Françoise Schiele, Catherine Sass & Sophie Visvikis (2000) ' Apolipoprotein E Polymorphisms and Concentration in Chronic Disease and Drug Responses ', Clinical Chemistry and Laboratory Medicine 38 (9). 841 - 852.
111. Sinding, Christiane (1996) ' Literary Genres and the Construction of Knowledge in Biology: Semantic Shifts and Scientific Change ', Social Studies of Science 26: 43 - 70.
112. Sjögren, M., C. Hesse, H. Basun, G. Köl, H. Thostrup, L. Kilander, J. Marcusson et al. (2001) ' Tacrine and Rate of Progression in Alzheimer's Disease-Relation to ApoE Allele Genotype ', Journal of Neural Transmission 108: 451 - 458.
113. Spear, Brian, Margo Heath-Chiozzi & Jeffrey Huff (2001) ' Clinical Applications of Pharmacogenetics ', Trends in Molecular Medicine 7 (5). 201 - 204.
114. Steimer, Werner & Julia Potter (2002) ' Pharmacogenetic Screening and Therapeutic Drugs ', Clinica Chimica Acta 315: 137 - 155.
115. Thomas, Francois & Geoffrey De Ribains (1998) Pharmacogenomics (London: Financial Times).
116. Tsai, Y.J. & H. Eugene Hoyme (2002) ' Pharmacogenomics: The Future of Drug Therapy ', Clinical Genetics 62: 257 - 264.
117. Van Lente, Harro & Arie Rip (1998a) ' The Rise of Membrane Technology: From Rhetorics to Social Reality ', Social Studies of Science 28 (2). 221 - 254.
118. Van Lente, Harro & Arie Rip (1998b) ' Expectations in Technological Developments: An Example of Prospective Structures to be Filled in by Agency ', in C. Disco & B. van der Meulen (eds). Getting New Technologies Together: Studies in Making Sociotechnical Order (Berlin: Walter de Gruyter): 203 - 227.
119. Vesell, Elliot (2000) ' Introduction ', Pharmacology 61: 118 - 123.
120. Weber, Wendell (2001) ' The Legacy of Pharmacogenetics and Potential Applications ', Mutation Research 479: 1 - 18.
121. Weinshilboum, Richard (2002) ' The Genomic Revolution and Medicine ', Mayo Clinic Proceedings 77 (8). 745 - 746.
122. Wilcock, Gordon, Sean Lilienfeld and Els Gaens, on behalf of the Galantamine International-1 Study Group (2000) ' Efficacy and Safety of Galantamine in Patients with Mild to Moderate Alzheimer's Disease: Multicentre Randomised Controlled Trial ', British Medical Journal (321) (9 December). 1 - 7.
123. Wilcock, Gordon, Sian MacGowan, Margaret Scott & D. Dawbarn (1995) ' Apolipoprotein E Genotype and Response to Tacrine in Alzheimer's Disease ', Poster presented at the International Psychogeriatrics Association Conference, Apolipoprotein E et Maladie d'Alzheimer, 29 May, Paris.
124. Winblad, B., K. Engedal, H. Soininen, F. Verhey, G. Waldemar, A. Wimo et al. (2001) ' A 1-Year, Randomized, Placebo-Controlled Study of Donepezil in Patients with Mild to Moderate AD ', Neurology 57: 489 - 495.
125. Wolf, C. Roland, Gillian Smith & Robert Smith (2000) ' Pharmacogenetics ', British Medical Journal 320 (8 April). 987 - 990.